ZIKV is a self-limited disease whose management consists of symptomatic supportive treatment with minor analgesic. Nonsteroidal anti-inflammatory drugs and aspirin should be avoided until Dengue infection could be ruled out. Multiple effective compounds have been described as having anti-ZIKV activity, but further research is needed to assess the efficacy in real infected patients. Currently, there is not an available vaccine yet. Candidate vaccines against ZIKV infection have shown promising data in efficacy in mice and non-human primates. The development of a ZIKV vaccine for humans is likely to be readily achievable within the next few years and several studies are now in Phase I.
KeywordsDengue Infection Central Nervous System Cell ZIKV Infection Reye Syndrome Flavivirus Infection
- 2.World Health Organization (2016) Psychosocial support for pregnant women and for families with microcephaly and other neurological complications in the context of Zika virus. http://appswhoint/iris/bitstream/10665/204492/1/WHO_ZIKV_MOC_166_engpdf?ua=. Accessed 5 Jan 2017Google Scholar
- 8.Sharma A, Lal SK (2017) Zika virus: transmission, detection, control, and prevention. Front Microbiol 8:e0005055Google Scholar
- 11.Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB (2016) In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. npj Vaccines. doi: 10.1038/npjvaccines.2016.21
- 13.Larocca RA, Abbink P, Peron JPS, de A Zanotto PM, Iampietro MJ, Badamchi-Zadeh A et al (2016) Vaccine protection against Zika virus from Brazil. Nature 536(7617):474–8Google Scholar